His stealth and strategic “greatness” might end up being a weakness. It remains to be seen so far as we are currently undervalued and continue to have significant delays. At some point Missling has to become forthcoming and reveal the cards he is currently holding. Or will he continue to kick the can indefinitely as some of the naysayers say on this board? If we do not have ReTT approval or at the very least file for approval sometime next year will you still be praising Misslings greatness? If we do not get Alz results by end of next year will you continue to praise him? As I understand it the goal of the CEO of a publicly traded company is to get a drug to market the quickest, most effective way possible. Missling is definitely not moving quickly. His effectiveness remains to be seen.
Most contributors were saying 2021 would be our year in 2020. That has now changed to 2022 will be our year. I hope we have a drug approved next year and do not continue to say next year will be our year!
Kudos arrow! Couldn't agree more. TGD has his plan and is all about successfully bringing that plan to fruition. Ne is solely focused on executing his plan, not hyping AVXL share price.
Neurology is a very complicated science. TGD is utilizing leading edge scientific tools to support A2-73 efficacy and that takes time to collate the huge amount of data.
We have to remember that AVXL 52 week low price is $3.75.
My guess is 1 year from now $17.00 will seem like a HUGE bargain as a result of hard positive data releases for RETT and PDD.
Patience all! We will be well rewarded as TGD's plan unfolds with many successes in the next 12 months.
Market Data 
Markets 
AI
